The detection of prostate cancer (PCa) 6 is closely related to prostate-specific antigen (PSA) but is limited by the low specificity of this biomarker (1 ) . Additional parameters such as the percentage of free PSA (%fPSA) (2 ) and other PSA subforms (3 ) or clinical parameters like prostate volume, age, and status of digital rectal examination (DRE) have demonstrated added value within multivariate models (4 ). However, biomarkers are still needed that can be used to detect aggressive PCa or that confer additional diagnostic value in patients with persistently increased PSA values and several previous negative biopsies. To address these needs, researchers have been focused on fPSA subforms [e.g., benign PSA, intact PSA, proprostate-specific antigen (proPSA)] (5 ). Of biomarkers in the latter category, [Ϫ2]proPSA has yielded promising results (6 ) , and its automated assay has been available since 2008 (7, 8 ) . When [Ϫ2]proPSA was combined with PSA and %fPSA to compute the prostate health index (Phi) using the formula: Phi ϭ [Ϫ2]proPSA/fPSA ϫ ͌PSA,%fPSA or [Ϫ2]proPSA alone (9, 10 ) . In 2012, [Ϫ2] proPSA was approved by the US Food and Drug Administration (FDA) to be used for initial biopsy decisions in men with PSA concentrations in the range of 4 -10 g/L and negative DRE.
The urine marker prostate cancer antigen 3 (PCA3) has been shown to increase the specificity of PSA, especially for patients with repeat biopsies (11) (12) (13) . This finding has resulted in the recent FDA approval in 2012 of the use of PCA3 for men scheduled for repeat biopsy. A correlation between PCA3 and biopsy outcome has been demonstrated (11, 13 ) , but within multivariate models PCA3 increased accuracy only modestly (13, 14 ) .
The detection of gene fusions of transmembrane protease, serine 2 (TMPRSS2) 7 to v-ets erythroblastosis virus E26 oncogene homolog (avian) (ERG) in PCa tissue (15 ) and its prevalence in approximately 50% of all PCa patients (16, 17 ) has been demonstrated. Based on these findings, a urinary assay for TMPRSS2:ERG fusion (T2:ERG) is currently in development using the same platform and technology as the PCA3 assay (18 ) . T2:ERG showed its clinical value for PCa detection in small cohorts (18, 19 ) and in a more recent multicenter study (20 ) .
Reviewed data have shown increased diagnostic accuracy with the use of PCA3 or T2:ERG (21 ) . Investigations with data on Phi and PCA3 (22 ) or PCA3 and T2:ERG have been performed (20, 23 ) , but a comparison of all 3 biomarkers in the same population has not been conducted so far. Therefore the aims of this study were to compare the clinical validity of Phi, PCA3, and T2:ERG in general and in different subpopulations of men who had undergone initial and repeated biopsies and to evaluate the diagnostic power of these biomarkers within a multivariate model. It can be assumed that the urinaryand serum-based markers, although they reflect different tissue situations and therefore differ in their diagnostic validity, might have substantially improved diagnostic power if used together.
Materials and Methods

STUDY POPULATION
We evaluated 320 samples from 281 men from 2 prostate cancer centers (center 1, Berlin, n ϭ 194; center 2, Muenster, n ϭ 126) from January 2009 to March 2012 (see flowchart in Fig. 1 ). The study was approved by both hospital ethics committees and reported in accordance with the Standards for the Reporting of Diagnostic Accuracy (24 ) . Urine and serum samples were collected from men scheduled for prostate biopsy (10 -22 cores) owing to suspicious DRE, suspicious transrectal ultrasonography findings, or increased PSA concentration or PSA velocity. Study exclusion criteria included urinary infections, medications (androgen or 5-␣-reductase inhibitors), or interventions that could alter PSA concentrations. Of the 281 patients included in this study, 35 were excluded for reasons of PSA Ͼ20 g/L (n ϭ 20), not giving consent for biopsy or not being biopsied within an appropriate timeframe (n ϭ 10), insufficient cells in urine for PCA3 measurement (n ϭ 2), and no fPSA measured (n ϭ 3). In addition, for 22 men with a total of 61 measurements, 39 repeated measurements (second, n ϭ 22; third, n ϭ 12; fourth, n ϭ 4; and fifth; n ϭ 1) were performed within the study period owing to repeat biopsies or active surveillance. Thus, these 39 samples after the first measurement were also excluded for the evaluation of data.
The final study cohort of 246 men included 110 PCa patients (45%). Of the 110 PCa patients, 37 had a suspicious DRE (34%). An initial biopsy was performed in 70 (64%) of the patients and 1-6 repeat biopsies in 40 (36%). One repeat biopsy was performed in 21 men, 2 in 8 men, 3 in 7 men, 4 in 3 men, and 6 repeat biopsies in 1 man. The Gleason scores at biopsy were distributed as follows: Gleason 5, n ϭ 2; Gleason 6, n ϭ 70; Gleason 7, n ϭ 29; Gleason 8, n ϭ 4; Gleason 9, n ϭ 4; and Gleason 10, n ϭ 1.
Of the 136 men with no evidence of malignancy (NEM), 109 had benign biopsy results (suspicious DRE, 14%) and 27 had the diagnosis of high-grade prostatic intraepithelial neoplasia (suspicious DRE, 11%), of whom 2 of 3 had at least 1 repeat biopsy. The 136 NEM patients included 66 (49%) with initial biopsy and 70 (51%) with 1-7 repeat biopsies, of whom 37 had 1, 17 had 2, 9 had 3, 4 had 4, 1 had 5, 1 had 6, and 1 had 7 repeat biopsies.
METHODS
Blood and urine sampling were done within 14 days before biopsy. Sample collection and storage were performed according to a recommended standard operating procedure for [Ϫ2]proPSA (25 ) . Thus, blood samples were centrifuged within 3 h and if analyzed within 48 h, serum was stored at 4°C. All other analyzed samples were stored at Ϫ70 or Ϫ80°C for a maximum of 3 years. Of the 126 serum samples from center 2, 123 were measured prospectively with PSA, fPSA, and [Ϫ2]proPSA. The remaining 3 samples from center 2 and all 194 samples from center 1 were analyzed retrospectively. All serum samples were processed by the Access 2 Immu-noassay System analyzer (Beckman Coulter), calibrated against the WHO standard for PSA and fPSA, with approximately 20%-25% lower values compared with traditional Hybritech calibration (26 ) . The analytical performance of the measurements assessed with control materials (Beckman Coulter) showed values within the allowed recommended limits.
After a DRE with 3 strokes per lobe as described earlier (27 ) , urine samples were collected (PRO-GENSA PCA3 urine sample collection kit, Hologic Gen-Probe), and the PROGENSA PCA3 assay and T2:ERG research test were performed retrospectively in all samples. The PCA3 score was calculated as: (mRNA PCA3)/(mRNA PSA) ϫ 1000. For T2: ERG the urine samples were processed similarly and the T2:ERG score was calculated as: (mRNA T2: ERG)/(mRNA PSA) ϫ 100000 (20 ) .
Transrectal ultrasonography was used to determine prostate volume. The Gleason scores were estimated according to the 2005 consensus conference of the International Society of Urological Pathology (28 ) .
STATISTICAL ANALYSIS
A sample size of 182 was needed assuming a 45% PCa positive biopsy rate and 2.5% nonevaluable study participants to demonstrate a sensitivity of 80% and a specificity of 50% within a CI of Ϯ10% at the 0.05 significance level (2-sided).
Statistical analyses were performed with SPSS version 19.0 (SPSS Inc) and MedCalc version 12.2.1 (MedCalc Software). Several tests (Mann-Whitney U-test, Kruskal Wallis test, McNemar test, and Spearman rank correlation coefficient) were performed and are indicated in the corresponding pas- sage of the text. Area under the curve (AUC) was estimated from ROC curves according to the method of DeLong et al. (29 ) . ROC curves were used to compare specificities at given sensitivities. P values Ͻ0.05 (2-sided) were considered significant.
To test the ability of Phi, PCA3, and T2 to improve specificity in detecting PCa at biopsy, these variables were used together in a multivariate artificial neural network (ANN) and binary logistic regression models with age, PSA, %fPSA, prostate volume, and DRE status as described previously in detail (30 ) . These models comprised only 1, 2, or all 3 new biomarkers without partial or full addition of the 5 traditional parameters PSA, %fPSA, prostate volume, age, and DRE status. Each of the ANN models had 3 layers: 1 input layer with 2-8 neurons, 1 hidden layer with 2 or 3 neurons, and 1 output neuron that ranged from 0 (low) to 1 (high PCa risk). ROC curve analyses for single parameters and ANN modeling using Bayesian regularization were performed with the whole data group or subgroups, respectively, and the leave-one-out approach was used for internal validation of the ANN models.
The models, including the calibration plots and the decision analysis (31 ) for models and single parameters, were constructed with MATLAB-software, especially the Neural Network Toolbox (Mathworks).
Results
CHARACTERISTICS AND SIGNIFICANCES OF THE STUDY GROUP
The 169 patients included from center 1 (77 PCa, 51 with initial biopsies; 92 NEM, 41 with initial biopsies) were first compared with 77 patients included from center 2 (33 PCa, 19 with initial biopsies; 44 NEM, 25 with initial biopsies). No significant differences were found between the 2 centers for age, prostate volume, PSA, %fPSA, Phi, PCA3, and T2:ERG (P 0.13-0.99). Only the DRE status (center 1, 40% DRE-positive PCa; center 2, 18% DRE-positive PCa) differed significantly between PCa patients (P ϭ 0.024). No difference was found between NEM patients from both centers (P ϭ 0.744). The difference in PCa patients was negligible because DRE was not an independent predictor in any model nor did the AUC for DRE differ between both centers (0.602 vs 0.594; P ϭ 0.87). AUCs for all other parameters did not differ significantly between centers 1 and 2 (P from 0.21-0.94). Thus, we evaluated the merged data of both centers.
PSA was not found to differ between PCa and NEM patients, but all other parameters were significantly different in univariate analysis, with the highest significance levels for the new markers PCA3, Phi, and T2:ERG (Table 1) . Almost all significance levels remained unchanged when we subdivided the study cohort in those with an initial biopsy or 1-7 repeat biopsies and in those with a PSA concentration of 1.6 -8 g/L (WHO calibration) or 2-10 g/L (traditional Hybritech calibration) regardless of whether DRE was negative or not.
ASSOCIATION BETWEEN CLINICOPATHOLOGICAL VARIABLES AND PCA3, Phi, AND T2:ERG
Correlation analyses were performed in all patients and in PCa patients separately (see Tables 1 and 2 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/ vol59/issue1). In brief, PCA3 and Phi were significantly correlated (r s ϭ 0.17; P ϭ 0.009) as were PCA3 and T2:ERG (r s ϭ 0.33; P Ͻ 0.0001) but not Phi and T2: ERG (r s ϭ 0.02; P ϭ 0.72). PCA3 and T2:ERG did not show any association with PSA or %fPSA (P from 0.14 -0.78), but Phi was strongly correlated with PSA (r s ϭ 0.4; P Ͻ 0.0001) and inversely with %fPSA (r s ϭ Ϫ0.44; P Ͻ 0.0001), as expected. In PCa patients, only PSA (r s ϭ 0.44; P Ͻ 0.0001) and Phi (r s ϭ 0.3; P ϭ 0.002) were strongly correlated with Gleason score, whereas PCA3, %fPSA, and T2:ERG were not (P 0.2-0.91).
ROC ANALYSES
In Table 2 and Fig 2, consistently had the largest and Phi the second largest AUC, although none of these AUC differences were significant (P 0.21-0.78). With the exception of the repeat biopsy group and %[Ϫ2]proPSA, which is very similar to Phi, the T2:ERG was always the third best parameter, and differences in AUCs vs Phi or %fPSA were never significant (P 0.08 -0.8). However, it should be pointed out that PCA3 showed higher specificity values (some of which were significantly higher) than all the other single markers from the clinically relevant threshold of 90% sensitivity upward. With a 90% sensitivity cutoff, 6%, 15%, or 20% of biopsies could have been avoided in the whole population with the use of Phi, PCA3, or the best model compared with PSA. All ANN models with the largest AUC in the respective groups were based only on Phi and PCA3, with the exception of the repeat biopsy group, for which the further addition of T2:ERG yielded in the best AUC ( Table 2 , Fig. 2B ). There was a modest but not statistically significant improvement over PCA3 alone when PCA3 and Phi (and in 1 case, T2:ERG) were added to the ANN model (AUC gains ranged from 0.01 to 0.04, P from 0.05 to 0.97). In the 3 groups with initial and repeat biopsies and PSA concentrations of 2-10 g/L with negative DRE, the ANN was not significantly different from Phi.
DECISION CURVE ANALYSIS
To compare the clinical usefulness of each single marker (32 ) with PSA and the classic ANN model with the variables age, PSA, %fPSA, prostate volume, and DRE status (model 1) as well as with the expanded ANN model in which PCA3 and Phi were included (model 2) or a model based only on PCA3 and Phi (model 3), decision curve analyses (DCA) were per- e The respective ANN model was built only with Phi and PCA3 except the repeat biopsy group, for which T2:ERG was the third input value.
PCA3, Phi, and TMPRSS2:ERG for Detecting PCa formed. The DCA of PCA3 and Phi (T2:ERG is not shown) showed a higher net benefit and larger useful probability range than PSA and %fPSA (see online Supplemental Fig. 1 ), whereas both ANN models with PCA3 and Phi had an increased net benefit against the classic ANN model (see online Supplemental Fig. 2) . The PCA3-and Phi-related ANN models also showed a better calibration than model 1 (see online Supplemental Fig. 3 ).
Discussion
There is an unquestioned need to supplement the information from PSA analysis to improve PCa detection and reduce unnecessary biopsy and overtreatment. PCA3 is already accepted as useful biomarker for patients undergoing repeat biopsies (11, 14, 33 ) as well as in initial biopsy cohorts (13, 34 ) . The combination of PSA, fPSA, and [Ϫ2]proPSA via the formula for Phi has been proven to enhance the diagnostic accuracy of PSA and %fPSA for pathological staging (35 ) and for early PCa diagnosis especially at initial biopsy (9, 36 ) . Recently, %[Ϫ2]proPSA and Phi have also been successfully tested in repeat biopsy patients, but in contrast with our study, data on %[Ϫ2]proPSA were better than on Phi (37 ) . During the preparation of this manuscript, a report of a study with combined data on Phi and PCA3 in 151 patients was published (22 ) . Data on urinary PCA3 and T2:ERG were available from a small cohort of 78 men (19 ) . The quantitative assay for T2:ERG was introduced later (18 ) , and data have been published on PCA3 and T2:ERG used together with PSA (20, 38 ) . To our knowledge, data from studies that have combined data on all 3 markers Phi, PCA3, and T2:ERG have not been available. In our study, Phi, PCA3, and T2:ERG showed significantly higher values in PCa patients compared with NEM patients, although PSA was equal (Table 1) . Our AUC data suggested that PCA3 had slightly improved diagnostic accuracy compared with Phi, although the AUCs were not statistically different (Table 2 ). In the recently published study by Ferro et al. (22 ) conducted with 151 initially biopsied patients, PCA3 and Phi also were noted to perform comparably. However, in our study PCA3 had the largest AUCs, and significant differences in specificity compared with Phi were reached at 90% sensitivity in the whole (34% vs 21%) and repeat biopsy (36% vs 19%) cohorts. This finding opens discussion about whether PCA3 should eventually be used as the best single parameter instead of PSA as the first line diagnostic test for PCa detection, as already discussed by Roobol et al. (39 ) . Another option could be to reserve PCA3 for those patients with repeat biopsies, for whom the advantage is the greatest over Phi in terms of AUC (0.08) and at 90% sensitivity (17% higher specificity). On the other hand, the combination of PSA, fPSA, and proPSA in the form of Phi should be preferred, owing to its high specificity at 90% sensitivity in the initial biopsy group, its economic advantage, and its lower discomfort for the patients. In- terestingly, although PCA3 was better than all other parameters except Phi and the ANN, Phi itself was significantly superior to %fPSA in only 2 cohorts. Comparison data of Phi to %fPSA were not provided by Ferro et al. (22 ) , but in other studies a significant improvement of Phi over %fPSA was also found (9, 36 ) . In the cohort with initial biopsies, Phi had the smallest AUC difference (0.02) compared with PCA3. Compared with PCA3, Phi performed best in the initial biopsy group, yielding an AUC of 0.68 compared to an AUC for PCA3 of 0.7 in this group and 0.71 in those patients with a negative DRE in the PSA range of 2-10 g/L. However, the small size of some subgroups was a limitation of our study. In 3 subgroups the calculated sample size of 182 could not be reached, so further comparisons in larger cohorts will be useful.
The usefulness of multivariable models was limited in this first study comparing PCA3, Phi, and T2: ERG. Ferro et al. (22 ) stated that multivariable analysis produced no significant model to improve the performance of their single biomarkers. Inclusion of all factors such as age, DRE status, prostate volume, PSA, %fPSA, or T2:ERG did not improve the AUC over the simple model with PCA3 and Phi only. About 10 years ago, there was a need to include rather inaccurate parameters such as prostate volume or the DRE status (40, 41 ) . It will be advantageous if these clinical parameters are no longer needed. A study by Chun et al. (14 ) showed a significant AUC gain (P ϭ 0.04) from 0.68 (for PCA3) to 0.73 (model) in a large study of 809 men with PCA3. A similar AUC gain from 0.8 (model without [Ϫ2]proPSA) to 0.85 was seen in one of the first studies using the automated [Ϫ2]proPSA assay (8 ) .
Regarding new single biomarkers, it should be emphasized that this study was the first to provide data on the quantitative urinary assay T2:ERG that included a comparison with the best available PCa biomarkers. T2:ERG demonstrated a slightly better performance compared with PSA and %fPSA, but no statistical significance was found. In this study, T2:ERG accuracy for predicting repeat biopsy outcome was lower than that observed in prior studies that used the same T2:ERG research assay (20, 42 ) . The overall performance in multivariable models was not improved by T2:ERG. However, the advantage of T2:ERG might be seen in subgroups of aggressive PCa. These investigations were not part of the present study. Our study was performed to show the performance of the quantitative T2:ERG assay and to compare this biomarker with those having the best diagnostic accuracy, such as PCA3 and Phi. Interestingly, correlations with the Gleason score were not seen with the PCa-specific urine markers but only with Phi and even more strongly with PSA.
To generate cutoff values, absolute values for PCA3, Phi, and T2:ERG are necessary but there are different recommendations, especially for PCA3. A sensitivity of 90% can be reached with an absolute PCA3 level of 15 on the basis of our data. In this study, the highest efficacy for a PCA3 value was found at 28 with 73% sensitivity and 64% specificity, which is very close to the FDA-approved cutoff of 25. A 90% sensitivity cutoff for Phi corresponded with a value of 27.5. At 90% sensitivity Phi improved specificity over that of %fPSA and PSA by 3% and 6%, whereas PCA3 prevented 15.4% and 18.4% and the ANN 20% and 23% of unnecessary biopsies compared with %fPSA and PSA, respectively. For the research assay of T2:ERG there are no existing cutoff recommendations so far. However, a 90% sensitivity cutoff would correspond to an absolute value of 2.3.
To summarize, PCA3 and Phi outperformed other analyzed biomarkers, whereas T2:ERG failed to significantly improve the ability to diagnose PCa. PCA3 reached the largest AUC and showed higher-specificity values than all the other single markers from the clinically relevant threshold of 90% sensitivity upward. Although PCA3 showed the largest advantage in the repeat biopsy cohort, Phi and PCA3 performed comparably in the initial biopsy cohort and in the 2-10 g/L PSA range cohort with negative DRE. The combination of both markers further enhanced the diagnostic power and the clinical utility as shown by DCA.
